The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMediumUpdated×3•Originally published 28 April 2026•Updated 28 April 2026•

1 min read

Novartis Reaffirms 2026 Guidance Despite Sales Dip from Generic Competition

Key Facts

1Novartis net sales declined 5% in constant currencies as growth drivers were offset by US generic erosion.

2Priority brands showed strong growth, with Kisqali up 55% and Pluvicto up 70% in constant currencies.

about 1 month ago

Version History

Version 3about 1 month ago

What changed: Updated to include strong performance of Kesimpta, Leqvio, and Rhapsido, while noting the faster-than-expected sales erosion of Entresto in the U.S.

Version 2about 1 month ago

What changed: Updated the story to include the 3% decline in premarket share price and confirmed that both sales and core operating profit missed market consensus.

Version 1about 1 month ago

What changed: Updated to reflect that core operating profit missed analyst estimates and identified Entresto as the specific drug facing generic competition.

Novartis shares declined approximately 3% after first-quarter results missed expectations, pressured by a faster-than-anticipated erosion of Entresto sales in the U.S. market. Despite these headwinds, the company saw strong outperformance from Kesimpta and Leqvio, alongside surging sales for Kisqali (up 55%) and Pluvicto (up 70%). Additionally, the drug Rhapsido is off to a robust start in the Chronic Spontaneous Urticaria (CSU) market, with further clinical trial readouts pending. Management reaffirmed its full-year 2026 guidance, expecting net sales to grow in the low single-digit range. This outlook suggests confidence in the innovative pipeline's ability to offset generic competition even as core EPS faced downward pressure. Investors remain focused on the scaling of these new launches to sustain long-term profitability.